Striking improvement with targeted therapy in an anaplastic lymphoma kinase-positive atypical giant congenital melanocytic naevus of the right lower limb: a case report
We report the case of a newborn with an atypical giant congenital melanocytic naevus (GCMN) of the right lower limb harbouring a ZEB2::ALK fusion. Treatment with an anaplastic lymphoma kinase (ALK) inhibitor led to a striking clinical response, allowing surgical debulking and functional limb preservation. This case highlights the potential role of targeted therapy in the management of an unresectable ALK-positive GCMN.
Authors
- Thai Hoa Tran
- Kyle R. Boulanger
- Andrée-Anne Roy
- Loubna Jouan (ORCID: https://orcid.org/0000-0001-7407-975X)
- Sandrine Essouri (ORCID: https://orcid.org/0000-0001-9144-0957)
- Nicolas Prud'homme (ORCID: https://orcid.org/0000-0002-4243-6916)
- Catherine McCuaïg (ORCID: https://orcid.org/0000-0003-0792-6247)
- Francis Fortin (ORCID: https://orcid.org/0000-0002-7110-4275)
- Jérôme Coulombe
- Victor Kokta
- Jessica McMahon
Institutions
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1093/bjd/ljaf334
- Primary Topic
- Cancer and Skin Lesions
- Type
- article
- Field-Weighted Citation Impact
- 0.00